The U.S. Federal Trade Commission said on February 17 that the FTC would file a lawsuit aimed at stopping the merger of Rhode Island’s two largest health care providers, Lifespan Corp. and Care New England Health System.
The U.S. antitrust regulator asked Biogen Inc. to present documents related to the approval and marketing of the company’s Alzheimer’s disease treatment, the drugmaker disclosed in a filing.
AstraZeneca’s $39 billion acquisition of Alexion is being investigated by the UK’s Competition and Markets Authority (CMA) to determine if the deal is anti-competitive.
A federal appeals court threw out an order requiring AbbVie Inc. and a partner to disgorge $448 million in profit for trying to keep generic versions of the blockbuster testosterone replacement drug AndroGel off the market.
The U.S. Federal Trade Commission sought additional information from Bristol-Myers Squibb Co. and Celgene Corp. and is focusing on the companies’ psoriasis treatments as part of the FTC’s review of their planned merger, Bristol-Myers said.
Ironwood Pharmaceuticals Inc. and Allergan plc announced that the companies reached an agreement with Mylan Pharmaceuticals Inc. resolving patent litigations brought in response to Mylan’s abbreviated new drug applications seeking approval to market generic versions of Linzess (linaclotide) before the expiration of the companies’ applicable patents.